Form 4: CONMED Corp CEO Pat Beyer Granted Stock Options

CONMED Corp's CEO, Pat Beyer, was granted 86,355 stock options under the company's 2018 Long-Term Incentive Plan.

Summary

• Pat Beyer, the President & CEO of CONMED Corp, was granted 86,355 stock options on January 2, 2025.
• The options were granted under the company's 2018 Long-Term Incentive Plan.
• The exercise price of the options is $67.35.
• The options generally vest in equal amounts over a five-year period.
• The expiration date for the options is January 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests.

Positives

• The grant of stock options aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the medical device industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the medical technology industry.
• Companies like Medtronic and Stryker also utilize stock options as part of their long-term incentive plans for executives.
• The vesting schedule of five years is fairly standard for these types of grants.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase shareholder value.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates